Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics


Checkpoint Therapeutics, Inc. (CKPT): $3.53

0.16 (+4.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CKPT POWR Grades


  • Sentiment is the dimension where CKPT ranks best; there it ranks ahead of 74.1% of US stocks.
  • CKPT's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • CKPT's current lowest rank is in the Stability metric (where it is better than 9.44% of US stocks).

CKPT Stock Summary

  • The ratio of debt to operating expenses for Checkpoint Therapeutics Inc is higher than it is for about just 0.49% of US stocks.
  • CKPT's price/sales ratio is 1,050.64; that's higher than the P/S ratio of 99.29% of US stocks.
  • As for revenue growth, note that CKPT's revenue has grown -78.92% over the past 12 months; that beats the revenue growth of merely 2.07% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Checkpoint Therapeutics Inc are ARDS, SVRA, GERN, BLCM, and GLYC.
  • Visit CKPT's SEC page to see the company's official filings. To visit the company's web site, go to www.checkpointtx.com.

CKPT Valuation Summary

  • In comparison to the median Healthcare stock, CKPT's price/sales ratio is 25118.42% higher, now standing at 958.3.
  • CKPT's price/sales ratio has moved up 860.2 over the prior 51 months.
  • CKPT's price/sales ratio has moved up 860.2 over the prior 51 months.

Below are key valuation metrics over time for CKPT.

Stock Date P/S P/B P/E EV/EBIT
CKPT 2021-08-31 958.3 4.7 -8.6 -6.5
CKPT 2021-08-30 940.6 4.6 -8.5 -6.4
CKPT 2021-08-27 901.8 4.4 -8.1 -6.0
CKPT 2021-08-26 880.9 4.3 -8.0 -5.8
CKPT 2021-08-25 883.8 4.3 -8.0 -5.9
CKPT 2021-08-24 857.2 4.2 -7.7 -5.6

CKPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CKPT has a Quality Grade of D, ranking ahead of 21.66% of graded US stocks.
  • CKPT's asset turnover comes in at 0.005 -- ranking 407th of 677 Pharmaceutical Products stocks.
  • VBIV, ARWR, and NOVN are the stocks whose asset turnover ratios are most correlated with CKPT.

The table below shows CKPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.005 1 4.869
2021-03-31 0.004 1 4.383
2020-12-31 0.033 1 3.944
2020-09-30 0.037 1 3.435
2020-06-30 0.061 1 3.348
2020-03-31 0.117 1 3.498

CKPT Price Target

For more insight on analysts targets of CKPT, see our CKPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.80 Average Broker Recommendation 1.4 (Strong Buy)

CKPT Stock Price Chart Interactive Chart >

Price chart for CKPT

CKPT Price/Volume Stats

Current price $3.53 52-week high $5.38
Prev. close $3.37 52-week low $2.16
Day low $3.33 Volume 844,500
Day high $3.58 Avg. volume 1,228,094
50-day MA $2.94 Dividend yield N/A
200-day MA $2.99 Market Cap 292.08M

Checkpoint Therapeutics, Inc. (CKPT) Company Bio


Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.


CKPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CKPT Latest Social Stream


Loading social stream, please wait...

View Full CKPT Social Stream

Latest CKPT News From Around the Web

Below are the latest news stories about Checkpoint Therapeutics Inc that investors may wish to consider to help them evaluate CKPT as an investment opportunity.

Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the 2021 Cantor Virtual Global Healthcare Conference, taking place on Monday, September 27, 2021, at 9:20 a.m. ET. Checkpoint management will also partici

Yahoo | September 22, 2021

Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows:

Intrado Digital Media | September 9, 2021

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | August 6, 2021

Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2021.

Intrado Digital Media | August 5, 2021

Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in the Ladenburg Thalmann 2021 Healthcare Conference, taking place July 13-14, 2021. The company will present a corporate update on Wednesday, July 14, 2021, at 11:30 a.m. ET and will also participate in one-on-one meetings during the confe

Yahoo | July 8, 2021

Read More 'CKPT' Stories Here

CKPT Price Returns

1-mo 16.50%
3-mo 19.66%
6-mo 10.31%
1-year 34.73%
3-year -1.26%
5-year N/A
YTD 33.21%
2020 54.07%
2019 -5.49%
2018 -53.09%
2017 N/A
2016 N/A

Continue Researching CKPT

Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:

Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8449 seconds.